Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Summary by The Manila Times
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying...

2 Articles

The Manila TimesThe Manila Times
Lean Right

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying...

·Manila, Philippines
Read Full Article
tipranks.comtipranks.com

Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today?

Prelude Therapeutics stock fell on Tuesday after the company announced an exclusive options agreement.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines on Tuesday, November 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Stock Markets icon

Stock Markets

Manila icon

Manila

Philippines Economy icon

Philippines Economy

News
For You
SearchBlindspotLocal